[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658711":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":36,"studyPopulation":37,"armGroups":38,"interventions":32,"overallOfficials":48,"centralContacts":53,"locations":32,"responsibleParty":59,"collaborators":32,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":32,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":32,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":85,"whyStopped":32,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":32},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Mean serum soluble BCMA level","Mean serum soluble B-cell maturation antigen (sBCMA) concentration measured by ELISA in ng\u002FmL.","Baseline",[14,17,20,23,26,29],{"measure":15,"description":16,"timeFrame":12},"Mean serum soluble BCMA in newly diagnosed multiple myeloma","Mean serum sBCMA level in newly diagnosed multiple myeloma patients.",{"measure":18,"description":19,"timeFrame":12},"Mean serum soluble BCMA in relapsed\u002Frefractory multiple myeloma","Mean serum sBCMA level in relapsed or refractory multiple myeloma patients.",{"measure":21,"description":22,"timeFrame":12},"Mean serum soluble BCMA in healthy controls","Mean serum sBCMA level in healthy control subjects.",{"measure":24,"description":25,"timeFrame":12},"Mean hemoglobin level","Mean hemoglobin concentration in g\u002Fd",{"measure":27,"description":28,"timeFrame":12},"Mean serum creatinine","Mean serum creatinine level in mg\u002FdL.",{"measure":30,"description":31,"timeFrame":12},"Mean bone marrow plasma cell percentage","Mean percentage of plasma cells in bone marrow aspirate.",null,{"allocation":32,"interventionModel":32,"interventionModelDescription":32,"primaryPurpose":32,"observationalModel":34,"timePerspective":35,"maskingInfo":32},"CASE_ONLY","PROSPECTIVE","Multiple myeloma is a malignant plasma cell disorder. Current monitoring relies on invasive bone marrow examination and monoclonal protein assays, which may be limited in oligosecretory disease.\n\nThis observational study will measure serum soluble BCMA levels in newly diagnosed and relapsed\u002Frefractory multiple myeloma patients and compare them with healthy controls. The relationship between sBCMA levels and clinical and laboratory disease characteristics will be assessed.","Patients with multiple myeloma and healthy controls attending South Egypt Cancer Institute, Assiut University.",[39,42,45],{"label":40,"type":32,"description":41,"interventionNames":32},"Newly Diagnosed Multiple Myeloma","Patients with newly diagnosed multiple myeloma before initiation of treatment.",{"label":43,"type":32,"description":44,"interventionNames":32},"Relapsed\u002FRefractory Multiple Myeloma","Patients with relapsed or refractory multiple myeloma after at least one prior line of therapy.",{"label":46,"type":32,"description":47,"interventionNames":32},"Healthy Controls","Age- and sex-matched healthy volunteers with normal CBC and renal function.",[49],{"name":50,"affiliation":51,"role":52},"Hossny B Hamed","Oncological Clinical Pathology Department South Egypt Cancer Institute, Assiut University","STUDY_CHAIR",[54],{"name":55,"role":56,"phone":57,"phoneExt":32,"email":58},"Naira A Ezz, Resident","CONTACT","+20 10 10119500","amennaira@gmail.com",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Naira Amen Ezz Eldeen Ahmed","Resident Physician, Department of Oncological Clinical Pathology","100658711","serum-soluble-bcma-as-a-non-invasive-marker-in-multiple-myeloma-100658711",false,"NCT07855718","Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma","Serum Soluble B-cell Maturation Antigen as a Non-Invasive Marker in Multiple Myeloma","Inclusion Criteria:\n\n* Group 1 (Newly Diagnosed MM):\n* Age 18 years or older\n* Newly diagnosed multiple myeloma according to WHO 2022 criteria\n* Pretreatment at time of sample collection\n\nGroup 2 (Relapsed\u002FRefractory MM):\n\n* Age 18 years or older\n* Confirmed multiple myeloma with documented relapse or refractory disease after at least one prior line of therapy\n\nGroup 3 (Controls):\n\n* Age 18 years or older\n* Healthy volunteers with normal CBC and renal function\n* Age and sex matched to patient groups\n\nExclusion Criteria:\n\n* \\- Other active malignancies or autoimmune diseases\n* Severe renal impairment (serum creatinine \\> 3.0 mg\u002FdL)\n* Active infection or inflammatory disease at sampling\n* Pregnancy or lactation",true,"ALL","18 Years",{"count":74,"type":75},90,"ESTIMATED","OBSERVATIONAL","This prospective study aims to investigate serum soluble B-cell maturation antigen (sBCMA) as a non-invasive marker in patients with multiple myeloma and to compare its levels with healthy controls.",[79],"Multiple Myeloma",[81,82,83,84],"Soluble BCMA","Multiple myeloma","Non-invasive marker","Assiut","NOT_YET_RECRUITING","2026-09-28",{"date":88,"type":89},"2026-10-02","ACTUAL",{"date":91,"type":75},"2026-09-30",{"date":93,"type":75},"2028-02-10",{"name":5,"class":6}]